Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE-3: Orforglipron vs Oral Semaglutide in Type 2 Diabetes with Metformin
jRCT2041230086Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of orforglipron in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from Baseline in Hemoglobin A1c (HbA1c). Started Nov 2023; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2041230086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230086.